Articles by Cody R. Barnett, MRA Director of Communications
Melanoma: What You Need to Know
Melanoma is the deadliest form of skin cancer. Rates of melanoma are rising rapidly, especially in younger people. In fact, cases of melanoma have tripled in the last 30 years, at a time when cancer rates for other common cancers have declined.
Do you know the answer to these top ten questions people ask about melanoma?
Melanoma Leaves a Mark – but Not Always the One You Think
Melanoma is no stranger to University of Delaware Senior Samantha Stinchcomb. In fact, this silent killer has been part of her life for the last 11 years – over half her life. She learned the hard way, at the sobering age of 13, that melanoma ‘isn’t just skin cancer’ when her father lost his three year battle with the disease. Since then, Samantha has been diligent about her own skin – and has had 16 precancerous moles removed. “It took my father, my best friend, from this earth and my life. In the almost 8 years since my dad’s been gone,” said Samantha. “I’ve also learned melanoma doesn’t plan on getting out of my life anytime soon.”
Our Research Saves Lives: MRA Grants Over $100 Million in Ten Years
Through powerful research, the Melanoma Research Alliance (MRA) is quickly delivering results and saving lives. In ten years, the Melanoma Research Alliance has become the largest, non-profit funder of melanoma research worldwide. In fact, with Tuesday's announcement of 28 new grant awards – MRA has now funded $100 million in the areas of prevention, diagnosis, and treatment!
Your Opportunity to Help Advance Melanoma Research
Beyond protecting yourself through sun-safety and skin-checks – one of the best ways you can observe Melanoma Awareness Month is by raising funds to support melanoma research!
Embrace Your Skin and Don't Be Anything that You Aren't
This freckled red head was never meant to be tan, but it didn’t stop her from trying. Stefani Schuetz just wanted that ‘perfect glow’ that she hoped would help her fit in after moving to Florida. She was training for a triathalon – a race requiring swimming, cycling, and running – with her sister when everything changed. Her sister thought she saw a bug on the back of her leg – but this bug turned out to be much worse. Instead of a bug, Stefani found a suspect mole that she’d never noticed before. She knew she had to get it checked out, but money was tight for this single Mom; it took her four months to make it to the dermatologist for a biopsy.
Libby Kistler: “I’m Still Here”
Statistically, Libby Kistler shouldn’t be here. She was diagnosed with Stage IIIB melanoma in 2005, before treatment for late-stage melanoma was transformed by immuno- and targeted therapies in 2011.
Immunotherapy & Chemotherapy – Two Different Approaches
We’ve all seen the movie where the heroic cancer patient bravely moves through treatment as she deals with nausea, hair loss, and other side effects. For many cancer patients this picture is true, however imprecise. Hollywood has conditioned us to equate cancer treatment with chemotherapy. Twenty years ago this narrative was more or less accurate, but in a world where immunotherapies and other new treatments are increasingly being used, this narrative isn’t keeping up with today’s reality. For some people with melanoma, this stuck-in-the-past narrative may even be deadly.
What’s Next in Melanoma Treatment?
Dr. Douglas Johnson, MRA Young Investigator awardee and Assistant Professor of Medicine and Melanoma Clinical Director at the Vanderbilt-Ingram Cancer Center, outlines three broad areas of current and future melanoma research.
Leveraged Finance Community Comes Together to Fight Melanoma
On May 23, 2018 more than one thousand professionals from the leveraged finance and finance community at-large will come together in the fight against melanoma for the seventh annual Leveraged Finance Fights Melanoma (LFFM) benefit and cocktail party. The event, held each year in the Rockefeller Center’s summer garden, has raised over $8.6 million to advance the Melanoma Research Alliance’s global research programs.
Melanoma is Determined, So is Eric
After 7 clinical trials, 8 surgeries, and more infusions than he can count --- Eric Martin is still here, seven years after being diagnosed with melanoma. He has had ups and downs and has tried practically every FDA-approved therapy for melanoma – but the crux of this story, which all readers need to understand, is that Eric’s fight isn’t yet finished. That’s because unlike many of the stories featured by MRA – Eric is still searching for his silver bullet and the elusive letters N.E.D. (no evidence of disease). He’s got big plans and melanoma isn’t going to get in the way. In short, Eric is a melanoma warrior.
About the Author
Cody R. Barnett, MRA Director of Communications
Cody R. Barnett joined the Melanoma Research Alliance (MRA) as Director of Communications in August of 2017. He works to develop and cultivate strategies, messages, and stories that propel MRA’s mission forward. Cody is responsible for media relations, web and social marketing, publications and materials development, and organizational branding. He is committed to using the power of visual, verbal, and written communications to promote MRA as a powerful force for advancing melanoma research.
Before joining the Melanoma Research Alliance, Cody served as Director of Communications at AIDS United, where he directed all internal, public, member, and online communications for the national HIV-focused organization. Previous to this, he managed digital communications for the Robert Wood Johnson Foundation’s Aligning Forces for Quality (AF4Q) initiative.
Cody earned his Master of Public Health (MPH), concentrating in health policy, from The George Washington University Milken Institute School of Public Health in 2013 and a Bachelor of Arts in political science from York College of Pennsylvania.